Steve Charlap

Steve Charlap pitches from a different chair than most angels in healthcare. He is an MD and MBA, founder of SOAP Health, and his investing thesis is grounded in a specific clinical conviction: that medical errors and missed diagnoses are an addressable problem and that early-stage AI is the lever that finally moves it. His checks reflect that view. They go into companies tackling diagnostic accuracy, clinical decision support, and AI tooling that sits in the actual exam-room workflow where errors happen.

The declared focus is AI/ML in healthcare and diagnostics. In practice, that means companies building clinical AI tools for primary care, specialty care, and diagnostic imaging, plus startups trying to compress the time and cognitive load on clinicians making complex decisions. He tends to be less interested in pure consumer wellness, in plays that ignore the clinician as an end user, and in software that wraps a regulatory question without engaging it. The bar is whether the product would actually reduce harm if deployed at scale, and whether the founders have the clinical literacy to build something a working physician would trust.

Checks run $25k-$100k, written into pre-seed and seed rounds. As with most clinician-angels at this size, the role is supporting capital rather than round-leading, but the signal carries weight in healthcare AI syndicates because his domain credibility is unusually deep. He is based in New York and most active in the US, particularly in companies with East Coast clinical anchors or relationships with academic medical centers, but he writes into Bay Area and remote-first companies as well when the thesis fits.

The team here is a single operator-investor, and the diligence style tracks his background. Expect detailed clinical questioning: what the workflow actually looks like, how the model handles edge cases that matter at the bedside, how the company is approaching FDA and reimbursement strategy, how the product will be sold to clinicians who already feel saturated. He is running SOAP Health as his day job, so engagement is concentrated and selective rather than broad.

For founders, the practical read is that Charlap is among the more useful clinician-angels for AI diagnostics and clinical decision support. The check is small but the credibility is meaningful, and the help skews toward the specific problems other investors cannot answer well: clinical evidence design, physician adoption, regulatory framing, and the realistic operational shape of a product that has to be trusted in a high-stakes setting. He is less useful for founders building consumer health apps with no clinical workflow component, for therapeutics, or for those who want passive capital. Founders building AI that touches medical decision-making and looking for a physician on the cap table who can stress-test the clinical assumptions will find him a high-quality early supporter and should pitch accordingly.